- Home
- TNON vs INTS Comparison
TNON vs INTS Comparison
Compare TNON & INTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNON
- INTS
- Stock Information
- Founded
- TNON 2012
- INTS 2012
- Country
- TNON United States
- INTS United States
- Employees
- TNON N/A
- INTS N/A
- Industry
- TNON Medical Specialities
- INTS Biotechnology: Pharmaceutical Preparations
- Sector
- TNON Health Care
- INTS Health Care
- Exchange
- TNON Nasdaq
- INTS Nasdaq
- Market Cap
- TNON 11.5M
- INTS 12.2M
- IPO Year
- TNON 2022
- INTS 2023
- Fundamental
- Price
- TNON $1.14
- INTS $0.41
- Analyst Decision
- TNON Strong Buy
- INTS Strong Buy
- Analyst Count
- TNON 2
- INTS 4
- Target Price
- TNON $5.50
- INTS $4.50
- AVG Volume (30 Days)
- TNON 987.5K
- INTS 87.7M
- Earning Date
- TNON 11-13-2025
- INTS 11-06-2025
- Dividend Yield
- TNON N/A
- INTS N/A
- EPS Growth
- TNON N/A
- INTS N/A
- EPS
- TNON N/A
- INTS N/A
- Revenue
- TNON $3,233,000.00
- INTS N/A
- Revenue This Year
- TNON $17.85
- INTS N/A
- Revenue Next Year
- TNON $85.60
- INTS N/A
- P/E Ratio
- TNON N/A
- INTS N/A
- Revenue Growth
- TNON N/A
- INTS N/A
- 52 Week Low
- TNON $0.85
- INTS $0.19
- 52 Week High
- TNON $5.85
- INTS $3.18
- Technical
- Relative Strength Index (RSI)
- TNON 43.47
- INTS 49.37
- Support Level
- TNON $1.11
- INTS $0.38
- Resistance Level
- TNON $1.30
- INTS $0.57
- Average True Range (ATR)
- TNON 0.05
- INTS 0.18
- MACD
- TNON -0.00
- INTS -0.02
- Stochastic Oscillator
- TNON 15.79
- INTS 11.18
About TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About INTS Intensity Therapeutics Inc.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.